BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1041 related articles for article (PubMed ID: 32006461)

  • 21. Nusinersen versus Sham Control in Later-Onset Spinal Muscular Atrophy.
    Mercuri E; Darras BT; Chiriboga CA; Day JW; Campbell C; Connolly AM; Iannaccone ST; Kirschner J; Kuntz NL; Saito K; Shieh PB; Tulinius M; Mazzone ES; Montes J; Bishop KM; Yang Q; Foster R; Gheuens S; Bennett CF; Farwell W; Schneider E; De Vivo DC; Finkel RS;
    N Engl J Med; 2018 Feb; 378(7):625-635. PubMed ID: 29443664
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunomodulatory treatment other than corticosteroids, immunoglobulin and plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy.
    Mahdi-Rogers M; Brassington R; Gunn AA; van Doorn PA; Hughes RA
    Cochrane Database Syst Rev; 2017 May; 5(5):CD003280. PubMed ID: 28481421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interventions for pityriasis rosea.
    Contreras-Ruiz J; Peternel S; Jiménez Gutiérrez C; Culav-Koscak I; Reveiz L; Silbermann-Reynoso ML
    Cochrane Database Syst Rev; 2019 Oct; 2019(10):. PubMed ID: 31684696
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanically assisted walking training for walking, participation, and quality of life in children with cerebral palsy.
    Chiu HC; Ada L; Bania TA
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD013114. PubMed ID: 33202482
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline.
    Garegnani L; Hyland M; Roson Rodriguez P; Escobar Liquitay CME; Franco JV
    Cochrane Database Syst Rev; 2021 Nov; 11(11):CD013720. PubMed ID: 34748221
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 - A Prospective Observational Study.
    Walter MC; Wenninger S; Thiele S; Stauber J; Hiebeler M; Greckl E; Stahl K; Pechmann A; Lochmüller H; Kirschner J; Schoser B
    J Neuromuscul Dis; 2019; 6(4):453-465. PubMed ID: 31594243
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment for speech disorder in Friedreich ataxia and other hereditary ataxia syndromes.
    Vogel AP; Folker J; Poole ML
    Cochrane Database Syst Rev; 2014 Oct; (10):CD008953. PubMed ID: 25348587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Protocol for a phase II, monocentre, double-blind, placebo-controlled, cross-over trial to assess efficacy of pyridostigmine in patients with spinal muscular atrophy types 2-4 (SPACE trial).
    Stam M; Wadman RI; Wijngaarde CA; Bartels B; Asselman FL; Otto LAM; Goedee HS; Habets LE; de Groot JF; Schoenmakers MAGC; Cuppen I; van den Berg LH; van der Pol WL
    BMJ Open; 2018 Jul; 8(7):e019932. PubMed ID: 30061431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antioxidants to prevent respiratory decline in people with Duchenne muscular dystrophy and progressive respiratory decline.
    Garegnani L; Hyland M; Roson Rodriguez P; Escobar Liquitay CM; Franco JV
    Cochrane Database Syst Rev; 2021 Dec; 12(12):CD013720. PubMed ID: 34850383
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conservative management following closed reduction of traumatic anterior dislocation of the shoulder.
    Braun C; McRobert CJ
    Cochrane Database Syst Rev; 2019 May; 5(5):CD004962. PubMed ID: 31074847
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacological treatment for pain in Guillain-Barré syndrome.
    Liu J; Wang LN; McNicol ED
    Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD009950. PubMed ID: 25855461
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interventions for chronic kidney disease-associated restless legs syndrome.
    Gopaluni S; Sherif M; Ahmadouk NA
    Cochrane Database Syst Rev; 2016 Nov; 11(11):CD010690. PubMed ID: 27819409
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies.
    Darras BT; Chiriboga CA; Iannaccone ST; Swoboda KJ; Montes J; Mignon L; Xia S; Bennett CF; Bishop KM; Shefner JM; Green AM; Sun P; Bhan I; Gheuens S; Schneider E; Farwell W; De Vivo DC;
    Neurology; 2019 May; 92(21):e2492-e2506. PubMed ID: 31019106
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Strength training and aerobic exercise training for muscle disease.
    Voet NB; van der Kooi EL; van Engelen BG; Geurts AC
    Cochrane Database Syst Rev; 2019 Dec; 12(12):CD003907. PubMed ID: 31808555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interventions for Old World cutaneous leishmaniasis.
    Heras-Mosteiro J; Monge-Maillo B; Pinart M; Lopez Pereira P; Reveiz L; Garcia-Carrasco E; Campuzano Cuadrado P; Royuela A; Mendez Roman I; López-Vélez R
    Cochrane Database Syst Rev; 2017 Nov; 11(11):CD005067. PubMed ID: 29149474
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-inflammatory medications for obstructive sleep apnoea in children.
    Kuhle S; Hoffmann DU; Mitra S; Urschitz MS
    Cochrane Database Syst Rev; 2020 Jan; 1(1):CD007074. PubMed ID: 31978261
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Long-Term Comparative Efficacy and Safety of Risdiplam and Nusinersen in Children with Type 1 Spinal Muscular Atrophy.
    Kokaliaris C; Evans R; Hawkins N; Mahajan A; Scott DA; Sutherland CS; Nam J; Sajeev G
    Adv Ther; 2024 Jun; 41(6):2414-2434. PubMed ID: 38705943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of nusinersen after one year of treatment in 123 children with SMA type 1 or 2: a French real-life observational study.
    Audic F; de la Banda MGG; Bernoux D; Ramirez-Garcia P; Durigneux J; Barnerias C; Isapof A; Cuisset JM; Cances C; Richelme C; Vuillerot C; Laugel V; Ropars J; Altuzarra C; Espil-Taris C; Walther-Louvier U; Sabouraud P; Chouchane M; Vanhulle C; Trommsdorff V; Pervillé A; Testard H; Lagrue E; Sarret C; Avice AL; Beze-Beyrie P; Pauly V; Quijano-Roy S; Chabrol B; Desguerre I
    Orphanet J Rare Dis; 2020 Jun; 15(1):148. PubMed ID: 32532349
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacological treatment for pain in Guillain-Barré syndrome.
    Liu J; Wang LN; McNicol ED
    Cochrane Database Syst Rev; 2013 Oct; (10):CD009950. PubMed ID: 24142399
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study.
    Finkel RS; Chiriboga CA; Vajsar J; Day JW; Montes J; De Vivo DC; Yamashita M; Rigo F; Hung G; Schneider E; Norris DA; Xia S; Bennett CF; Bishop KM
    Lancet; 2016 Dec; 388(10063):3017-3026. PubMed ID: 27939059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 53.